MediciNova (NASDAQ:MNOV) is up 13% premarket on light volume in reaction to the announcement of encouraging preclinical results on an intranasal RSV vaccine by SARS-CoV-2 vaccine development partner BioComo.
The RSV vaccine, based on BP-PIV and VLP-BC-PIV platform technology developed by BioComo and Mie University, induced high neutralizing antibody titers in mice.
BC-PIV, a non-transmissible viral vector derived from the recombinant human parainfluenza virus type 2 (hPIV2), is the same vector used in their intranasal COVID-19 vaccine candidate.
The RSV vaccine mouse study was conducted at Fraunhofer Institute (IZI) for Cell Therapy and Immunology in Leipzig, Germany. MNOV plans to work with IZI on animal studies for the COVID-19 vaccine.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.